4D Molecular Therapeutics与大冢制药达成协议，授予其在亚太地区对 4D-150基因疗法的权利4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy

动脉网2025-11-03

by GOAI由GOAI生成Share To分享到4D Molecular Therapeutics (4DMT) has entered into an exclusive license agreement with Otsuka Pharmaceutical for the development and commercialization of 4D-150 in the Asia-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2580171302?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-03 17:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2580171302","market":"us","top_or_hot":-1,"title":"4D Molecular Therapeutics与大冢制药达成协议，授予其在亚太地区对 4D-150基因疗法的权利4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy","media":"动脉网","content":"<div>\n<p>by GOAI由GOAI生成Share To分享到4D Molecular Therapeutics (4DMT) has entered into an exclusive license agreement with Otsuka Pharmaceutical for the development and commercialization of 4D-150 in the Asia-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110317061794ebc090&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4D Molecular Therapeutics与大冢制药达成协议，授予其在亚太地区对 4D-150基因疗法的权利4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4D Molecular Therapeutics与大冢制药达成协议，授予其在亚太地区对 4D-150基因疗法的权利4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-03 17:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110317061794ebc090&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by GOAI由GOAI生成Share To分享到4D Molecular Therapeutics (4DMT) has entered into an exclusive license agreement with Otsuka Pharmaceutical for the development and commercialization of 4D-150 in the Asia-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110317061794ebc090&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110317061794ebc090&s=b","article_id":"2580171302","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110317061794ebc090&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2580171302","pubTimestamp":1762160640,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"by GOAI由GOAI生成Share To分享到4D Molecular Therapeutics  has entered into an exclusive license agreement with Otsuka Pharmaceutical for the development and commercialization of 4D-150 in the Asia-Pacific region. The collaboration focuses on advancing treatment options for eye diseases, particularly targeting wet age-related macular degeneration  and diabetic macular edema ..4D Molecular Therapeutics与大冢制药达成了一项独家许可协议，授权其在亚太地区开发和商业化4D-150。This partnership aims to leverage Otsuka’s regional expertise alongside 4DMT’s proprietary technology platform to expand access to innovative treatments for patients suffering from these conditions..该合作伙伴关系旨在利用大冢的区域专业知识和4DMT的专有技术平台，扩大这些疾病患者获得创新治疗的机会。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","BK4539":"次新股","FDMT":"4D Molecular Therapeutics","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"4D Molecular Therapeutics reaches agreement with Otsuka Pharmaceutical to grant it rights to 4D-150 gene therapy in Asia Pacific 4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"FDMT":1.5},"content_text":"by GOAI由GOAI生成Share To分享到4D Molecular Therapeutics (4DMT) has entered into an exclusive license agreement with Otsuka Pharmaceutical for the development and commercialization of 4D-150 in the Asia-Pacific region. The collaboration focuses on advancing treatment options for eye diseases, particularly targeting wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME)..4D Molecular Therapeutics（4DMT）与大冢制药达成了一项独家许可协议，授权其在亚太地区开发和商业化4D-150。此次合作的重点是推进眼科疾病治疗方案，特别是针对湿性年龄相关性黄斑变性（湿性AMD）和糖尿病性黄斑水肿（DME）。Under the terms of the agreement, Otsuka will hold exclusive rights to develop, manufacture, and market 4D-150 in specified countries within the Asia-Pacific region. 4D-150 is a gene therapy product designed to address retinal diseases by inhibiting vascular endothelial growth factor (VEGF), which plays a key role in disease progression.根据协议条款，大冢将拥有在亚太地区特定国家开发、生产和销售4D-150的独家权利。4D-150是一种基因治疗产品，旨在通过抑制血管内皮生长因子（VEGF）来应对视网膜疾病，该因子在疾病进展中起关键作用。This partnership aims to leverage Otsuka’s regional expertise alongside 4DMT’s proprietary technology platform to expand access to innovative treatments for patients suffering from these conditions..该合作伙伴关系旨在利用大冢的区域专业知识和4DMT的专有技术平台，扩大这些疾病患者获得创新治疗的机会。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1For any suggestion and feedback, please contact us.如有任何建议和反馈，请联系我们。Date: November 3, 2025日期：2025年11月3日Related posts:相关文章：Drug Patent Watch Analysis: Biosimilar Switching Studies Need Standardization, Examination of 15 Studies Shows药物专利观察分析：生物类似药转换研究需要标准化，15项研究的检查显示ACL Restructuring Could Undermine Efficiencies Gained Since its Aging and Disability Services ConsolidationACL重组可能削弱自其老龄化和残疾人服务整合以来取得的效率Emcure Pharmaceuticals Partners with Sanofi India to Distribute Amaryl and Cetapin for Diabetes Management埃默尔制药与赛诺菲印度合作分销用于糖尿病管理的Amaryl和CetapinAdvancements in CAR T Cell Therapy Show Effectiveness in Treating Hematologic MalignanciesCAR T细胞疗法的进展显示出治疗血液系统恶性肿瘤的有效性©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 版权所有。与我们合作：[email protected]电子邮件地址Author作者GOAIGOAIRelated Post相关文章News Flash新闻快讯AAVantgarde Secures $141 Million Series B Funding to Advance Gene Therapy for Inherited Eye DiseasesAAVantgarde获得1.41亿美元的B轮融资，以推进遗传性眼病的基因治疗。2025-11-032025年11月3日","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580171302","isCrawlerRequest":true}